A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Abstract. Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer.
Jun 22, 2012 ˇ Women who carry mutations in BRCA1 or BRCA2 are at a substantially increased risk of developing breast and/or ovarian cancers. Lifetime risks ...
People also ask
What is the life expectancy of someone with BRCA2?
Are the BRCA1 and BRCA2 genes associated with an increased risk of ovarian cancer?
What cancer is associated with mutations of the BRCA1 gene?
What is the most common cause of breast cancer a mutation in either BRCA1 or BRCA2?
Dec 6, 2012 ˇ Correction: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 ...
Conclusion: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in ...
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer ...
SWE-BRCA. / A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...
The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and ...